Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approved for administering to individuals of all ages against pneumococcal disease, an infection caused by streptococcus pneumoniae bacteria. Internal Medicine portfolio includes approximately 17 specialties and seven therapy areas, including respiratory, multivitamin and multimineral, gastrointestinal, pain, neuroscience, cardiovascular and women’s healthcare. Pfizer Hospital Business Unit focuses on providing advanced anti-infectives to institutions such as hospitals and nursing homes. Inflammation and Immunology focuses on discovering and developing novel therapeutics for chronic autoimmune diseases. Its brands include Prevenar13, CorexDX, Dolonex, Enbrel, Becosules and Folvite, among others.
Pfizer Financial Highlights
- Revenue: Pfizer reported revenue of ₹867.69 crore in FY09 vs ₹982.61 crore in FY08. It showed a decrease of 11.70% on a yearly basis.
- Operating Profit: Pfizer reported an operating profit of ₹210.01 crore in FY09 vs ₹419.13 crore in FY08. It showed a decrease of 49.89% on a year-on-year basis.
- Net Profit: Pfizer reported a net profit of ₹137.12 crore in FY09 vs ₹299.58 crore in FY08. It showed a decrease of 54.23% on a yearly basis.